Skip to main content

Cancer and Leukemia Group B adjuvant chemotherapy trials in postmastectomy breast cancer patients


The Cancer and Leukemia Group B (CALGB) has conducted two recent trials of adjuvant chemotherapy in breast cancer patients found to have lymph node metastases after mastectomy. The first trial in 772 evaluable patients demonstrated an advantage of five drugs (CMFVP) over three drugs (CMF). This advantage is seen in the group of patients who have been followed the longest period of time (median 52 months). When the more recent entries are also included in the evaluation, the benefit is seen only in women with more than three positive nodes. The advantage of five drugs over three is seen first and most dramatically in those patients with the greatest burden of disease and only later, and less dramatically, appears in groups with fewer positive lymph nodes. The second trial examines the effects of two scheduling methods of CMFVP and the value of a non-cross-reacting drug combination during the second six months of a year of adjuvant therapy.

This is a preview of subscription content, access via your institution.


  1. Tormey DC, Falkson G, Weiss RB, Perloff M, Glidewell OJ, Holland JF: Postoperative chemothrapy with/without immunotherapy for mammary carcinoma: a preliminary report.In SE Jones, SE Salmon (eds). Adjuvant Therapy of Cancer II. Grune and Stratton, New York, 1979, pp 253–260

    Google Scholar 

  2. Weiss RB, Tormey DC, Holland JR, Weinberg VE, Lesnick GJ, Perloff M, Falkson G, Glidewell OJ: A randomized trial of postoperative 5-drug vs 3-drug chemotherapy after mastectomy: a cancer and leukemia group B study. Rec Results Cancer Res 80:170–176

  3. Tormey DC, Weinberg VE, Holland JF, Weiss RB, Glidewell OJ, Perloff M, Falkson G, Falkson HC, Henry PH, Leone LA, Rafla S, Ginsberg SJ, Silver RT, Blom J, Carey RW, Schein PS, Lesnick GJ: A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer: a cancer and leukemia group B study. Journal of Clinical Oncology (in press 1983)

  4. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, DeLena M, Tancini G, Bajetta E, Musumeci R, Veronesi U: Combination chemotherapy as an adjuvanttreatment in operable breast cancer. N Engl J Med 293:405–410, 1976

    Google Scholar 

  5. Canellos GP, Pocock SJ, Taylor SC III, Sears ME, Klaasen DJ, Band PR: Combination chemotherapy for metastatic breast carcinoma: prospective comparison of multiple drug therapy with-phenylalanine mustard. Cancer 38:1882–1886, 1976

    PubMed  Google Scholar 

  6. Cooper, RG, Holland JF, Glidewell O: Adjuvant chemotherapy of breast cancer. Cancer 44:793–798, 1979

    PubMed  Google Scholar 

  7. Weiss DW: MER and other mycobacterial fractions in the immunotherapy of cancer. Med Clin North Am 60:473–497 1976

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations



Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wood, W.C., CALGB. Cancer and Leukemia Group B adjuvant chemotherapy trials in postmastectomy breast cancer patients. Breast Cancer Res Tr 3 (Suppl 1), S39–S43 (1983).

Download citation

  • Issue Date:

  • DOI:


  • adjuvant chemotherapy
  • CMF
  • non-cross-reacting drug combinations